The Division of Hematology/Oncology is actively involved in clinical research. We are all members of the Children’s Oncology Group (international) and currently have 67 therapeutic and biology studies open at CHEO.

The division is involved in research that includes:

  • LCH IV – international collaborative treatment protocol for children and adolescents with Langerhans cell histiocytosis
  • Oral rivaroxaban in venous thrombosis
  • Applying Biomarkers to long term effects of childhood cancer treatment
  • Dabigatran anticoagulant therapy
  • OsteonecrosisOsteonecrosis in children with acute lymphoblastic leukemia
  • Electronic pain diary for youths with cancer
  • Dose finding study of melatonin in children with relapsed solid tumors
  • Impact of school visits on siblings of children with cancer
  • Predicting the risk of infection in children receiving chemotherapy for acute myeloid leukemia
  • Development of the Pediatric Supportive Care Scale (P-SCS)
  • Validation of a myelodysplasia-specific measure of quality of life
  • Inherited bone marrow failure syndromes
  • Idiopathic thrombocytopenic purpura (ITP) quality of life instrument
  • Thalassemia major quality of life instrument for pediatrics and adult
  • Myelodysplasia-specific quality of life instrument
  • Blood borne pathogens surveillance project
  • ITP therapy with intravenous immunoglobulin (IVIg) versus IVIG with steroids
  • Prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer
  • Survey of lost to follow-up childhood cancer survivors
  • Transition to meaningful activity for childhood cancer survivors
  • Implementation, validation and evaluation of fluorescence in situ hybridisation (FISH)
  • Development and usability of an online self-management and transitional care program for youth with cancer
  • Canadian hemophilia database (CHARMS)
  • National sickle cell registry

Related Links

Back to top